UnitedHealth Group (UNH) and Humana (HUM) both delivered impressive stock performances in April, though UnitedHealth emerged as the slight winner with a 37% gain compared to Humana's 36%. The rally for UnitedHealth culminated with its stock closing at $370.48 on April 30, while Humana's shares closed at $236.44. The momentum behind both stocks was driven primarily by CMS finalizing a 2% increase in Medicare Advantage payment rates for 2027, a decision that released over $13 billion into the program and relieved significant regulatory pressure on medical loss ratios (MLR). This positive regulatory environment also coincided with softer Q1 2026 hospital volumes at peers like HCA Healthcare, which implied lower utilization and reduced medical costs for managed care payers. Fundamentally, UnitedHealth reported strong Q1 2026 earnings on April 21, delivering adjusted EPS of $7.23 against an expected $6.61 and revenue of $111.72 billion. The company further improved its medical cost ratio by 90 basis points to 84% and raised full-year adjusted EPS guidance to greater than $18.25, with CEO Stephen Hemsley highlighting efforts to modernize healthcare. Bank of America responded with a "Buy" upgrade and a $435 price target. In contrast, Humana reported its Q1 2026 results on April 29 with adjusted EPS of $10.31 versus $10.20 expectations on revenue of $39.65 billion. Humana's individual Medicare Advantage membership surged approximately 22% year-over-year, adding roughly 1.14 million members, and the company affirmed full-year guidance of at least $9 in adjusted EPS and $160 billion in revenue, prompting analysts Guggenheim and UBS to raise their price targets significantly. Despite April's gains, the broader recovery for UnitedHealth appears more durable; its stock is up 11.63% year-to-date compared to Humana's decline of 9.14%. Both companies benefit from demographic tailwinds, specialty drug volume growth, and an improving rate environment, but UnitedHealth maintains a competitive advantage through its diversified Optum platform which spans pharmacy benefit management, healthcare services, and data analytics. Humana remains more concentrated in Medicare Advantage, leaving it more exposed to Star Ratings headwinds and v28 risk model phase-ins. While cash generation is robust for both—UnitedHealth generated $8.91 billion in operating cash flow while Humana saw a 279% year-over-year jump to $1.25 billion—bear concerns persist regarding regulatory risk, potential reacceleration of MLR pressure, and stretched valuations.